Nextcure SEC Filings

Key take-aways from the Form 4 filed on 24-Jun-2025

NextCure, Inc. (ticker: NXTC) reported that director Elaine V. Jones received a non-derivative compensation grant consisting of a stock option for 18,700 common shares on 20-Jun-2025. The award carries an exercise price of $0.47 and expires 19-Jun-2035. The option vests 100 % on the earlier of 20-Jun-2026 or the date of the company’s 2026 annual shareholders’ meeting, providing a one-year vesting horizon.

The transaction is coded “A” (acquisition) and increases Ms. Jones’ derivative holdings to 18,700 options, all held directly. No common shares were sold or otherwise disposed, and the filing does not reference a Rule 10b5-1 trading plan.

The incremental dilution is negligible: the option grant equates to roughly 0.06 % of NextCure’s ~28.9 million shares outstanding (latest available figure). As such, the filing is viewed as routine director compensation rather than a signal of fundamental change. The document contains no financial or earnings data and does not affect previously issued guidance.

The latest Form 4 for NextCure, Inc. (ticker: NXTC) reports that director David S. Kabakoff received an equity-based compensation award of 28,050 stock options on 20 June 2025. The options carry an exercise price of $0.47 per share, expire on 19 June 2035, and are owned directly by the director. A single “A” transaction code indicates the acquisition of derivative securities; no open-market purchase or sale of common stock is involved.

Per the footnote, the award vests in full on the earlier of 20 June 2026 or the 2026 Annual Meeting of Stockholders. After the grant, Kabakoff’s beneficial ownership in derivative securities stands at 28,050 options. The filing contains no additional non-derivative holdings, no 10b5-1 trading plan disclosure, and no amendments to prior filings.

Because this is a routine director compensation grant under the company’s incentive plan, it does not change NextCure’s cash position and produces only minimal potential dilution already anticipated in the plan’s share reserve. Investors may view the low strike price as an incentive to drive long-term shareholder value, but the transaction itself is unlikely to have a material near-term impact on NXTC’s share price or fundamentals.

Form 4 filing overview

On 24 June 2025, NextCure, Inc. (NXTC) reported that director Anne Elizabeth Borgman was granted a stock option for 18,700 common shares at an exercise price of $0.47 per share. The grant date was 20 June 2025 (transaction code “A”). The option vests in full on the earlier of 20 June 2026 or the 2026 annual shareholders’ meeting and carries an expiration date of 19 June 2035.

No open-market acquisitions or dispositions of common stock were disclosed, and the director’s post-transaction beneficial holding consists of 18,700 derivative securities held directly. Because this is a routine equity-incentive award rather than a purchase or sale, immediate valuation impact is minimal, but the disclosure illustrates continued use of option grants to align board incentives with shareholder interests.

NextCure director Stephen W. Webster received a stock option grant on June 20, 2025, representing a significant insider transaction. Key details include:

• Granted 18,700 stock options to purchase common stock
• Exercise price set at $0.47 per share
• Options expire on June 19, 2035
• Full vesting occurs on the earlier of June 20, 2026 or the 2026 Annual Meeting

This director compensation grant suggests continued board engagement and alignment with shareholder interests through equity-based incentives. The relatively low exercise price compared to typical market prices for biotech stocks may indicate current market challenges or strategic considerations in retention of board talent.

NextCure, Inc. (NXTC) – Form 4 insider filing

On 24 June 2025, director Ellen Feigal filed a Form 4 reporting the grant of a stock option on 20 June 2025. The option covers 18,700 shares of common stock at an exercise price of $0.47 per share. It vests in full on the earlier of 20 June 2026 or the date of NextCure’s 2026 Annual Meeting of Stockholders and carries an expiration date of 19 June 2035. Ownership is reported as direct.

No open-market purchases or sales of common shares were disclosed, and no additional derivative or non-derivative transactions were listed. After the grant, Dr. Feigal’s beneficial ownership consists solely of these 18,700 option shares.

The filing represents a routine equity incentive award to a director and does not convey new operational or financial performance data.